The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders
Jeffrey M. Witkin, Arnold Lippa, Jodi L. Smith, Xiaoming Jin, Xingjie Ping, Andrew Biggerstaff, Bronwyn M. Kivell, Daniel E. Knutson, Dishary Sharmin, Kamal P. Pandey, Md Yeunus Mian, James M. Cook, Rok Cerne
Topics & Concepts
Neuroactive steroidMedicineDepression (economics)Preclinical researchPharmacologyNeurosciencePsychiatrySafety profileDrug developmentNeurologyAllosteric regulationClinical pharmacologySafety pharmacologyDosingDrug discoveryAllosteric modulatorDrugNeuroprotectionBioinformaticsAdverse effectAntidepressantSedationPsychopharmacologyPsychologyIntensive care medicineFirst generationNeuroscience and Neuropharmacology ResearchGABA and Rice ResearchSleep and Wakefulness Research